Treeline Biosciences Inc. has patented new tetrahydroisoquinoline heterobifunctional proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1)-targeting moiety potentially useful for the treatment of cancer.